A Phase 1a/1b, first-in-human, open-label, non-randomized, multicentre, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with an anti-PD1 monoclonal antibody (cemiplimab) in subjects with advanced solid tumours.